妇儿健康导刊2025，Vol.4Issue(5)：193-198,6.DOI:10.3969/j.issn.2097-115X.2025.05.041
乌司他丁联合促红细胞生成素在胎龄<32周合并呼吸窘迫综合征患儿中的应用效果
Application effect of Ulinastatin combined with Erythropoietin in children with respiratory distress syndrome of gestational age<32 weeks
摘要
Abstract
Objective To study the application effect of Ulinastatin combined with Erythropoietin in children with respiratory distress syndrome of gestational age<32 weeks.Methods A total of 120 children with respiratory distress syndrome with gestational age<32 weeks admitted to the Department of Neonatology,the Affiliated Hospital of Guilin Medical University from July 2019 to December 2020 were selected and divided into four groups with 30 cases in each group according to random number table method.The control group was given conventional combined treatment,on the basis of the control group,the ulinastatin group was given Ulinastatin treatment,the erythropoietin group was given Erythropoietin treatment,and the combination group was given Ulinastatin combined with Erythropoietin treatment.The levels of serum hepatocyte growth factor(HGF),transforming growth factor βl(TGF-β1)and vascular endothelial growth factor(VEGF)in bronchoalveolar lavage fluid were compared among the four groups at 1,24,48 and 72 hours after administration,and mechanical ventilation time,oxygen dependence time,hospitalization time,bronchopulmonary dysplasia(BPD)and adverse reactions were compared among the four groups.Results The levels of HGF and VEGF in the combination group were higher than those in the other three groups at each time point after administration(P<0.05).The levels of TGF-β1 at 24,48 and 72 hours after administration were lower than those in the other three groups(P<0.05).The mechanical ventilation time,oxygen dependence time and hospitalization time of the combination group were shorter than those of the other three groups,and the incidence of BPD in the combination group was 10.00%,which was lower than of 60.00%,36.67%,and 33.33%in the control group,ulinastatin group,and erythropoietin group,respectively(P<0.05).There was no difference in the total incidence of adverse reactions among the four groups(P>0.05).Conclusion Ulinastatin combined with Erythropoietin in children with respiratory distress syndrome of gestational age<32 weeks can increase the levels of HGF and VEGF,reduce the level of TGF-β1,shorten the time of mechanical ventilation,oxygen dependence and hospitalization,and the incidence of BPD,which can provide an effective treatment for respiratory distress syndrome in preterm infants.关键词
早产儿/呼吸窘迫综合征/乌司他丁/促红细胞生成素Key words
Preterm infant/Respiratory distress syndrome/Ulinastatin/Erythropoietin分类
医药卫生引用本文复制引用
刘曼,赵庭鉴,周勇..乌司他丁联合促红细胞生成素在胎龄<32周合并呼吸窘迫综合征患儿中的应用效果[J].妇儿健康导刊,2025,4(5):193-198,6.基金项目
广西壮族自治区卫生健康委员会自筹经费科研课题(Z20190519). （Z20190519）
